Domenica Rubino, EASD 2022: Semaglutide 2.4 mg vs Liraglutide 3.0 mg – STEP 8 Post-hoc analysis

The aim of the STEP 8 trial (NCT04074161) was to compare the effect and safety of semaglutide 2.4 mg once weekly compared to liraglutide 3.0 mg once daily on weight management in people with obesity. In this touchENDOCRINOLOGY interview, Dr Domenica Rubino (Washington Center for Weight Management and Research, Arlington, VA , USA) discusses the post-hoc analyses of the STEP 8 trial evaluating the effects of semaglutide 2.4 mg vs liraglutide 3.0 mg on glucose metabolism, in patients with prediabetes at baseline.

The abstract entitled: ‘Semaglutide 2.4 mg improved glucose metabolism and reverted prediabetes to normoglycaemia in adults with overweight or obesity vs liraglutide 3.0 mg (STEP 8) ‘ was presented at the European Association for the Study of Diabetes, 19-23 Sept, 2022.

Questions:

1. What did the STEP 8 study teach us about the effect of semaglutide and liraglutide on weight loss in patients with prediabetes? (0:15)
2. What were the aims and design of this analysis of the STEP 8 study? (1:02)
3. What were the findings in terms of glucose metabolism and glycaemic status? (3:01)

Disclosures: Domenica Rubino is a consultant for and discloses grant/research support from Boehringer Ingelheim and Novo Nordisk.

Support: Interview supported by Touch Medical Media. Interview conducted by Shanice Allen.

Recorded as a highlight of EASD 2022

#semaglutide #liraglutide #STEP8